CSIMarket Company Name, Ticker, Industry, else..
 
Mink Therapeutics Inc   (NASDAQ: INKT)
 
Price: $11.5900 $0.18 1.578%
Day's High: $11.68120002746582 Week Perf: -4.45 %
Day's Low: $ 11.31 30 Day Perf: 3.3 %
Volume (M): 4,167 52 Wk High: $ 16.98
Volume (M$): $ 0 52 Wk Avg: $11.86
Open: $11.47 52 Wk Low: $8.48



 Market Capitalization (Millions $) 58
 Shares Outstanding (Millions) 5
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Business Description


Mink Therapeutics Inc is a biotechnology company that focuses on developing targeted mRNA therapies for treating various diseases. The company's approach involves using modified mRNA molecules to produce therapeutic proteins within the patient's cells, aiming to address the underlying causes of diseases at a genetic level. Mink Therapeutics aims to leverage mRNA technology to create personalized treatments for a range of conditions, including rare genetic disorders, cancer, and infectious diseases. The company utilizes its proprietary platform and expertise in mRNA therapeutics to advance its drug development pipeline and potentially revolutionize the field of gene therapy.


   Company Address: 149 Fifth Avenue New York 10010 NY
   Company Phone Number: 994-8250   Stock Exchange / Ticker: NASDAQ INKT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CCCC        1.03% 
CRIS   -4.31%    
ELUT        1.25% 
ENTX        7.89% 
INBX   -6.41%    
IOVA        28.93% 
• View Complete Report
   



Clinical Study

Efficacy of Allo-iNKT Cell Therapy agenT-797 in PD-1 Refractory Solid Tumors Findings from SITC 2025

Published Fri, Nov 7 2025 3:43 PM UTC

: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agenT-797, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The findings indicate durable responses and significant immune reactivation in p...
Clinical Study

MiNK Therapeutics Unveils Promising Allo-iNKT Cell Therapy Combination to Tackle Advanced Gastroesophageal Cancers at...

Published Thu, Jan 23 2025 7:44 PM UTC

In a significant advancement in cancer treatment, MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering clinical-stage biopharmaceutical company, showcased its innovative approach to tackling advanced gastroesophageal cancers at the esteemed American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium held in San Francisco, California. The company is com...
Clinical Study

MiNK Therapeutics' Clinical Data Reveals Promising Results for AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Refractory Gastric Cancer Therapy

Published Wed, May 22 2024 11:30 AM UTC

MiNK Therapeutics Presents Promising Clinical Activity of AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Gastric Cancer PatientsNew York, May 22, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a leading clinical-stage biopharmaceutical company specializing in allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other ...
Financing Agreement

MiNK Therapeutics Raises $5.8 Million in Private Placement and Bolsters Clinical Trials with Board Observer Appointment

Published Mon, May 13 2024 11:30 AM UTC

MiNK Therapeutics Secures $5.8 Million in Private Placement and Adds Board Observer for Accelerated Clinical Trials of MiNK-215
NEW YORK, May 13, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a trailblazing clinical-stage biopharmaceutical company focused on the development, discovery, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT)...
Clinical Study

New York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed promising preclinical data for its investigational iNKT cell therapy, MiNK-215, targeting colorectal cancer liver metastases. The announcement was made during the American Association for Cancer Research (AACR) Meeting held in San Diego, CA.MiNK Therapeutics is focused on developing and commercia...

Published Mon, Apr 8 2024 4:00 PM UTC

MiNK Therapeutics Announces promising preclinical activity of MiNK-215 against colorectal cancer liver metastases at AACRNew York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed promising preclinical data for its investigational iNKT cell therapy, MiNK-215, targeting colorectal cancer liver metastases. The announcement was made durin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.16
Working Capital Ratio 1.23
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.45 $
Revenues (TTM) -
Cash Flow (TTM) 2.51 $
Cash 1.75 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -757,361
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.